Lim Jonathan E
Lim Jonathan E's purchase track record
How the stock did after each of Lim Jonathan E's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/5/2023 | ERAS | $1.70M | +29.7% | +49.1% | +15.9% |
| 10/5/2023 | ERAS | $2.03M | +1.9% | -1.4% | +20.9% |
| 6/8/2023 | ERAS | $275K | -4.0% | -32.0% | +6.8% |
| 3/28/2023 | ERAS | $284K | -5.8% | -22.6% | +7.6% |
| 1/10/2023 | ERAS | $231K | -23.7% | -26.7% | +13.3% |
| 12/14/2022 | ERAS | $200K | -34.1% | -44.0% | +9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BOLD trades near support amid sector news. Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Transaction History
| MAZE | ▼ Sell | Other | 37,724 | — | 2/3/2025 | View on chart |
| MAZE | ▼ Sell | Other | 270,232 | — | 2/3/2025 | View on chart |
| BOLD | ▼ Sell | Other | 525,274 | — | 4/2/2024 | View on chart |
| ERAS | ▲ Buy | Open Market | 278,150 | $478K | 12/6/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 721,850 | $1.2M | 12/5/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 1,000,000 | $2.0M | 10/5/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 100,000 | $275K | 6/8/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 100,000 | $284K | 3/28/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 60,000 | $231K | 1/10/2023 | View on chart |
| ERAS | ▲ Buy | Open Market | 40,000 | $200K | 12/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pompe Disease Market Expected to Grow Through 2036
A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.
Pompe Disease Market Expected to Grow Through 2036. A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.